Effectiveness of dabrafenib in the treatment of patients with BRAF V600–mutated metastatic melanoma in a Named Patient Program-Reference-Cited by-同舟云学术

Effectiveness of dabrafenib in the treatment of patients with BRAF V600–mutated metastatic melanoma in a Named Patient Program

Published:2019-10 Issue:5 Volume:29 Page:527-532
ISSN:0960-8931
Container-title:Melanoma Research
language:en
Short-container-title:

Author:

Martin-Algarra Salvador,Hinshelwood Rebecca,Mesnage Soizick,Cebon Jonathan,Ferrucci Pier Francesco,Aglietta Massimo,Neyns Bart,Chiarion-Sileni Vanna,Lindsay Colin R.,Del Vecchio Michele,Linardou Helen,Merelli Barbara,Tonini Giuseppe,Atkinson Victoria,Freivogel Klaus,Stein Dara,Dalland Lindi,Lau Mike,Legenne Philippe,Queirolo Paola,Millward Michael

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Dermatology,Oncology

Reference15 articles.

1. The global burden of cancer 2013.;Fitzmaurice;JAMA Oncol,2015

2. Updates in therapy for advanced melanoma.;Singh;Cancers (Basel),2016

3. New strategies in melanoma: entering the era of combinatorial therapy.;Sullivan;Clin Cancer Res,2015

4. Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma.;Ascierto;J Clin Oncol,2013

5. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.;Hauschild;Lancet,2012

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Brain metastasis from the perspective of molecular mechanisms and treatment, presenting a new approach for targeting ion channels by nano drugs;Exploration of Neuroscience;2024-04-10

2. Systemic Therapy for Melanoma Brain and Leptomeningeal Metastases;Current Treatment Options in Oncology;2023-12

3. Understanding Real-World Treatment Patterns and Clinical Outcomes among Metastatic Melanoma Patients in Alberta, Canada;Current Oncology;2023-04-13

4. Retrospective Chart Review of Dabrafenib Plus Trametinib in Patients with Metastatic BRAF V600-Mutant Melanoma Treated in the Individual Patient Program (DESCRIBE Italy);Targeted Oncology;2021-11

5. A Retrospective Analysis of Dabrafenib and/or Dabrafenib Plus Trametinib Combination in Patients with Metastatic Melanoma to Characterize Patients with Long-Term Benefit in the Individual Patient Program (DESCRIBE III);Cancers;2021-05-18